Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+१.२५%
१,११०.४७
+१३.७५
+१.२५%
—१,०९६.७२१,०९८.७४१,११३.८२१,०९८.७४——
SIXC
Communications
SIXC
Communications
SIXC
-१.१९%
६०४.०७
-७.२५
-१.१९%
—६११.३२६११.३२६११.३२६०३.३३——
SIXE
Energy
SIXE
Energy
SIXE
+२.५६%
१,२०१.४९
+२९.९५
+२.५६%
—१,१७१.५४१,१७६.१५१,२०२.३८१,१७६.१५——
SIXI
Industrials
SIXI
Industrials
SIXI
+१.०१%
१,७६५.३०
+१७.६७
+१.०१%
—१,७४७.६३१,७४७.६७१,७७०.५११,७४४.४३——
SIXM
Financials
SIXM
Financials
SIXM
-०.१७%
६३०.४२
-१.०७
-०.१७%
—६३१.४९६३१.२३६३३.९०६२७.९५——
SIXR
Staples
SIXR
Staples
SIXR
-१.००%
८४१.४५
-८.४९
-१.००%
—८४९.९४८५०.२३८५०.२३८३६.२०——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+०.३५%
२१८.८३
+०.७७
+०.३५%
—२१८.०६२१८.०६२१९.९६२१८.०२——
SIXT
Technology
SIXT
Technology
SIXT
+१.३१%
३,५८२.२३
+४६.२०
+१.३१%
—३,५३६.०३३,५४९.४२३,५९०.५२३,५४३.३८——
SIXU
Utilities
SIXU
Utilities
SIXU
+०.९७%
९१३.८९
+८.८२
+०.९७%
—९०५.०७९०८.०७९१६.८३९०७.६८——
SIXV
Health care
SIXV
Health care
SIXV
-०.३८%
१,४४४.३३
-५.५३
-०.३८%
—१,४४९.८६१,४५१.३४१,४६४.४५१,४४०.७५——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-०.७२%
२,४१२.९६
-१७.५१
-०.७२%
—२,४३०.४७२,४१५.८४२,४२२.९५२,३९६.१४——
ABVX:EPA
Abivax SA
€ १०४.६०
+०.४८%
(+०.५०) 1D
मे १२, १२:३७:५४ GMT+२  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
€ १०२.३०
High
€ १०४.७०
Low
€ १०२.२०
Mkt. cap
८.३४ अरब
Avg. vol.
१.२३ लाख
Volume
११.८९ हजार
52-wk high
€ १३२.००
52-wk low
€ ५.००
EPS
-€ ४.८३
Shares outstanding
७.९७ करोड
No. of employees
६९
News stories
From sources across the web
Stock Titan
Stock Titan
·
१४ घण्टा पहिले
Abivax investors sign off on 2025 results, pay and financing powers
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees६९
Founded२०१३ डिसेम्बर ४
Headquarters-
Sector-
Websiteabivax.com
Last report
२०२६ मार्च २३
Fiscal Period
Q4 2025
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
१९.१४ लाख / १३.४६ लाख
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
९.७० लाख
१०.४७ लाख
६.३९ लाख
१९.१४ लाख
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
३.९३ करोड
३.८६ करोड
५.५४ करोड
४.४४ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
८८.९३ लाख
८९.४४ लाख
२.७३ करोड
२.७७ करोड
Operating expense
४.८२ करोड
४.७५ करोड
८.१४ करोड
७.३६ करोड
Total operating expenses
४.८२ करोड
४.७५ करोड
८.१४ करोड
७.३६ करोड
Operating income
-४.७२ करोड
-४.६५ करोड
-८.०७ करोड
-७.१६ करोड
Other non operating income
४.३१ लाख
२६.५५ लाख
-७.४२ करोड
-४९.६० लाख
EBT including unusual items
-५.२४ करोड
-४.८४ करोड
-१५.३४ करोड
-७.६१ करोड
EBT excluding unusual items
-५.१३ करोड
-४.८४ करोड
-१५.३४ करोड
-८.०८ करोड
Income tax expense
-
-
-
५८.४८ लाख
Effective tax rate
-
-
-
-७.६८%
Other operating expenses
-२४.०० हजार
-४६.०० हजार
-१४.०४ लाख
१४.७४ लाख
Net income
-५.२४ करोड
-४.८४ करोड
-१५.३४ करोड
-८.२० करोड
Net profit margin
-५,३९८.९७%
-४,६२४.०७%
-२३,९९९.६९%
-४,२८२.१३%
Earnings per share
-
-
-
-
Interest and investment income
८.५९ लाख
१.९० लाख
३३.६१ लाख
११.९० लाख
Interest expense
-४५.३५ लाख
-३५.२१ लाख
-४२.१३ लाख
-१.५३ करोड
Net interest expenses
-३६.७६ लाख
-३३.३१ लाख
-८.५२ लाख
-१.४१ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-४.७१ करोड
-४.६५ करोड
-८.०६ करोड
-७.०८ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer